The Short Version
Strong mechanistic and regulatory evidence supports that antibacterial soaps — particularly those containing triclosan — contribute to antibiotic resistance development. Multiple peer-reviewed studies show triclosan exposure selects for bacteria with cross-resistance to clinical antibiotics, and the FDA banned triclosan from consumer soaps in 2016 partly on these grounds. However, the claim overgeneralizes: triclosan-based soaps are now largely off the market, the evidence gap between laboratory findings and real-world population-level causation persists, and not all antibacterial soap ingredients carry the same risk profile.